Therapure Biopharma Inc..'s biologics division, Evolve Biologics, confidentially submitted a draft registration statement for an IPO in the U.S.

The IPO is expected to commence after the U.S. Securities and Exchange Commission completes its review process, subject to market and other conditions.

The Mississauga, Canada-based privately held company's biologics unit separates proteins from blood's plasma for use in treating diseases.